for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ambu A/S

AMBUb.CO

Latest Trade

122.80DKK

Change

-3.20(-2.54%)

Volume

2,734,392

Today's Range

117.20

 - 

126.90

52 Week Range

85.30

 - 

203.70

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Ambu Proposes Lars Rasmussen As New Chairman

Nov 13 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: CHANGES WITHIN THE BOARD OF DIRECTORS OF AMBU A/S.CHAIRMAN OF BOARD OF DIRECTORS JENS BAGER HAS INFORMED BOARD OF DIRECTORS THAT AFTER 9 YEARS OF SERVICE HE WISHES TO RESIGN FROM BOARD OF DIRECTORS.JENS BAGER WILL RESIGN AS OF AMBU'S ANNUAL GENERAL MEETING IN DECEMBER 2019.PROPOSES THAT LARS RASMUSSEN IS ELECTED AS NEW CHAIRMAN OF BOARD OF DIRECTORS AT ANNUAL GENERAL MEETING..LARS RASMUSSEN IS, AMONG OTHERS, CHAIRMAN OF BOARD OF DIRECTORS OF COLOPLAST A/S AND H. LUNDBECK A/S.PROPOSES THAT BRITT MEELBY JENSEN, CEO OF SWEDISH MEDTECH COMPANY ATOS MEDICAL AB, IS ELECTED AS NEW MEMBER OF BOARD.

Ambu Q4 EBIT Before Special Items Decreases To DKK 18 Mln

Nov 13 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: ANNUAL REPORT 2018/19 (EARNINGS RELEASE).REG-AMBU A/S: ANNUAL REPORT 2018/19 (EARNINGS RELEASE).EXPECT TO LAUNCH OUR DUODENOSCOPE IN EARLY Q4 2019/20.BOARD OF DIRECTORS PROPOSES THAT DIVIDEND OF DKK 0.38 (DKK 0.40) BE PAID PER SHARE, CORRESPONDING TO A DECREASE OF 5% AND AN UNCHANGED PAY-OUT RATIO OF 30%.AMBU - FY 2019/20 OUTLOOK: ORGANIC GROWTH IN RANGE OF 16-22%.AMBU - FY 2019/20 OUTLOOK: EBIT MARGIN BEFORE SPECIAL ITEMS IN RANGE OF 12-14%.AMBU - FY 2019/20 OUTLOOK: SALES OF SINGLE-USE ENDOSCOPES OF APPROX. 900,000 UNITS.EXPECTS LIST PRICE OF DUODENOSCOPE TO BE IN RANGE USD 1,400-1,600.HAS BEEN DECIDED TO ESTABLISH A GLOBAL CO-MARKETING AGREEMENT, WHEREBY AMBU AND COOK MEDICAL WILL BE WORKING TOGETHER ON INTRODUCING DUODENOSCOPE TO HOSPITALS NOT ONLY IN USA BUT ON ALL MAJOR MARKETS.REVENUE FOR FINANCIAL YEAR WAS DKK 2,820M (DKK 2,606M) BASED ON ORGANIC GROWTH OF 4% (15%).Q4 ORGANIC GROWTH OF -19% (15%) WAS REALISED IN Q4, BASED ON REVENUE OF DKK 606M (DKK 729M).Q4 EBIT BEFORE SPECIAL ITEMS DECREASED TO DKK 18M (DKK 165M) WITH AN EBIT MARGIN BEFORE SPECIAL ITEMS OF 3.0% (22.6%).Q4 2018/19 REVENUE DKK 606 MILLION VERSUS DKK 729 MILLION YEAR AGO.UNIT SALES IN 2018/19 WAS 618,000 ENDOSCOPES AGAINST 560,000 UNITS LAST YEAR, CORRESPONDING TO A GROWTH RATE OF 10% (54%).

Ambu Q3 EBIT Before Special Items Rises To DKK 155 Mln

Aug 22 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: INTERIM REPORT FOR Q3 2018/19.AMBU - REPEATS FY OUTLOOK REVISED AS RESULT OF AGREEMENT TO TRANSITION US PARTNERSHIP.IN Q3, AMBU HAS ACHIEVED SOLID ORGANIC GROWTH OF 10% AND AN EBIT MARGIN BEFORE SPECIAL ITEMS OF 20.1%.FOR Q3, REVENUE TOTALLED DKK 773M (DKK 673M), WITH ORGANIC GROWTH OF 10% AND REPORTED GROWTH OF 15%.Q3 ORGANIC GROWTH OF 15% WAS REALISED IN NORTH AMERICA, 5% IN EUROPE AND 9% IN THE REST OF THE WORLD..AMBU - IMPACT OF AGREEMENT ON US PARTNERSHIP ON BIG FIVE 2020 STRATEGY: ORGANIC GROWTH IN 2019/20 IS NOW ESTIMATED IN THE RANGE OF 16-22% COMPARED TO PREVIOUSLY 16-19%.Q3 GROSS MARGIN FOR Q3 WAS 56.4% (59.7%.SALES OF SINGLE-USE ENDOSCOPES IN Q3 TOTALLED 194,000 UNITS, UP 33% RELATIVE TO Q3 LAST YEAR.AMBU - IMPACT OF AGREEMENT ON US PARTNERSHIP ON BIG FIVE 2020 STRATEGY: SALE OF APPROX. 900,000 ENDOSCOPE UNITS IN 2019/20 COMPARED TO PREVIOUSLY APPROX. 1,000,000.Q3 EBIT BEFORE SPECIAL ITEMS FOR THE QUARTER WAS DKK 155M (DKK 151M).

Ambu Says FY Financial Guidance Revised

Aug 21 (Reuters) - Ambu A/S <AMBUb.CO>::AMBU INVESTS INTO A 100% DIRECT SALES ORGANISATION FOR PULMONOLOGY IN THE US.AS PART OF ONGOING INITIATIVE TO EXPAND DIRECT SALES FORCE, CO & TRI-ANIM MUTUALLY AGREED TO FULLY TRANSITION SALES OF ASCOPE PRODUCTS TO AMBU.FY FINANCIAL GUIDANCE IS REVISED.SEES FY 2019 REVENUE GROWTH WILL BE REDUCED BY APPROXIMATELY 8% -PTS.SEES FY EBIT MARGIN BEFORE SPECIAL ITEMS REDUCED BY APPROX. 4%-PTS.SEES FY FREE CASH FLOW TO BE REDUCED BY APPROX. DKK 175 MILLION.

Ambu A/S Is Expanding Its Product Portfolio And Commercial Infrastructure

June 17 (Reuters) - Ambu A/S <AMBUb.CO>::IS EXPANDING ITS PRODUCT PORTFOLIO AND COMMERCIAL INFRASTRUCTURE.FINANCIAL OUTLOOK ADJUSTED TO REFLECT COMMERCIAL INVESTMENTS AND NEW PRODUCT LAUNCH TIMELINES.LAUNCH OF CYSTOSCOPE INTO UROLOGY MARKET IS EXPECTED TO COME EARLIER THAN EXPECTED.TOTAL INCREMENTAL COST IS ESTIMATED TO BE DKK 225M IN 2019/20.EXPANSION WILL MORE THAN DOUBLE CO'S GLOBAL VISUALIZATION SALESFORCE.HIRING WILL START IN Q4 2018/19 WITH AN ESTIMATED COST IN 2018/19 OF APPROX. DKK 20M.SEES EBIT-MARGIN BEFORE SPECIAL ITEMS OF APPROX. 22% COMPARED TO PREVIOUSLY STATED 22-24% FOR CURRENT FISCAL YEAR 2018/19.SEES FOR CURRENT FY ORGANIC GROWTH OF APPROX. 14-15% COMPARED TO PREVIOUSLY STATED 15-16%.SEES FREE CASH FLOWS OF APPROX. DKK 375M COMPARED TO PREVIOUSLY STATED DKK 400-475M FOR CURRENT FISCAL YEAR 2018/19.REASON FOR ADJUSTMENT OF GROWTH IS DUE TO DISCONTINUATION OF SC210.ADJUSTMENT OF EBIT MARGIN IS DRIVEN BY LOWER GROWTH AND INVESTMENTS IN COMMERCIAL INFRASTRUCTURE.EXPECTATION IS TO SELL APPROX. 1.000.000 ENDOSCOPES UNITS IN 2019/20 COMPARED TO PREVIOUSLY STATED +1,000,000.ORGANIC GROWTH IN 2019/20 IS ESTIMATED IN RANGE OF 16-19% COMPARED TO PREVIOUSLY 18-23.SPECIAL ITEMS RELATED TO REPLACEMENT OF AMBU'S CEO ARE UNCHANGED AND EXPECTED TO BE DKK 38M.

Cook Medical, Ambu Announce Collaboration To Address Endoscope-Related Infections

May 18 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: COOK MEDICAL AND AMBU ANNOUNCE COLLABORATION TO ADDRESS ENDOSCOPE-RELATED INFECTIONS.COOK MEDICAL AND AMBU ANNOUNCE COLLABORATION TO ADDRESS ENDOSCOPE-RELATED INFECTIONS.COOK MEDICAL, CO HAVE AGREED ON TERMS TO ENTER INTO PARTNERSHIP IN WHICH COOK WILL DISTRIBUTE CO'S SINGLE-USE, DISPOSABLE DUODENOSCOPE IN U.S..NO FURTHER DETAILS ABOUT AGREEMENT WITH COOK MEDICAL WILL BE DISCLOSED AT THIS TIME.AGREEMENT IS NOT EXPECTED TO HAVE ANY IMPACT ON OUTLOOK FOR AMBU CONCERNING GROWTH, EARNINGS OR FREE CASH FLOWS TOWARDS SEPTEMBER 2020.AMBU IS CURRENTLY PURSUING REGULATORY CLEARANCE FROM U.S. FDA FOR ITS SINGLE-USE DUODENOSCOPE.

Ambu Appoints New CEO

May 10 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: AMBU APPOINTS NEW CEO.APPOINTED JUAN-JOSÉ GONZALEZ AS NEW CEO,.REPLACEMENT OF CEO DOES NOT CHANGE ANNOUNCED FINANCIAL EXPECTATIONS FOR 2018/19.NEW CEO, EFFECTIVE MAY 15, 2019, TO REPLACE LARS MARCHER WHO RESIGNS FROM HIS POSITION..IN RELATION TO LARS MARCHER'S RESIGNATION, THERE WILL BE ONE-OFF COSTS OF APPROX. DKK 38M, WHICH FOR ACCOUNTING PURPOSES WILL BE RECOGNIZED IN INCOME STATEMENT AS SPECIAL ITEMS.PLANNED PRODUCT LAUNCHES UP TO END OF FINANCIAL YEAR 2019/20 AND AMBU'S PROGRAM FOR UPCOMMING DDW CONGRESS IN SAN DIEGO ON 18-21 MAY 2019 IS THUS UNAFFECTED BY THIS.

Ambu Q2 EBIT Rises To DKK 195 Million

May 1 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: INTERIM REPORT FOR Q2 2018/19 AND FOR THE PERIOD 1 OCTOBER 2018 - 31 MARCH 2019.REG-AMBU A/S: INTERIM REPORT FOR Q2 2018/19 AND FOR THE PERIOD 1 OCTOBER 2018 - 31 MARCH 2019.Q2 2018/19 REVENUE DKK 785M MILLION VERSUS DKK 651 MILLION YEAR AGO.OVERALL, THIS WAS AMBU'S BEST-EVER QUARTER.SALES OF ENDOSCOPES REACHED 182,000 UNITS FOR QUARTER AND 331,000 UNITS FOR H1.WE ARE CONFIDENT THAT TOTAL SALES OF AT LEAST 750,000 ENDOSCOPES WILL BE ACHIEVED BY END OF YEAR -CEO.OUTLOOK FOR FULL YEAR ANNOUNCED IN INTERIM REPORT FOR Q1 2018/19 ON 31 JANUARY 2019 IS MAINTAINED.Q2 2018/19 EBIT DKK 195 MILLION VERSUS DKK 156 MILLION YEAR AGO.AMBU REALISED ORGANIC GROWTH OF 14% IN Q2.AT END OF MARCH, WE LAUNCHED A NEW SINGLE-USE ENDOSCOPE FOR ENT PROCEDURES IN EUROPE, AND WE EXPECT TO LAUNCH PRODUCTS IN US MARKET BEFORE SUMMER -CEO.Q2 WAS A QUARTER OF MANY SUCCESSES, AND WE ARE UP TO SPEED ON ALL IMPORTANT PARAMETERS BEFORE START OF H2 -CEO.

Ambu Q1 2018/19 EBIT Rises To DKK 112 Million

Jan 31 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: INTERIM REPORT FOR Q1 2018/19.REG-AMBU A/S: INTERIM REPORT FOR Q1 2018/19.IN Q1, AMBU REALISED ORGANIC GROWTH OF 15% AND A 43% INCREASE IN SALES OF ENDOSCOPES TO 149,000 UNITS..OUTLOOK FOR FINANCIAL YEAR ANNOUNCED IN ANNUAL REPORT FOR 2017/18 ON 13 NOVEMBER 2018 IS MAINTAINED.REVENUE OF DKK 656M (DKK 553M) WAS POSTED FOR Q1.Q1 2018/19 EBIT DKK 112 MILLION VERSUS DKK 91 MILLION YEAR AGO.SALES OF ENDOSCOPES IN Q1 REACHED 149,000 UNITS (104,000 UNITS), UP 43% RELATIVE TO Q1 LAST YEAR.."WE ARE SEEING AN INCREASING EFFECT OF APPROX. 50 EXTRA SALES REPRESENTATIVES HIRED IN USA OVER PAST YEAR".

Ambu Q4 EBIT Increases to DKK 165 Mln

Nov 13 (Reuters) - Ambu A/S <AMBUb.CO>::REG-AMBU A/S: ANNUAL REPORT 2017/18 (EARNINGS RELEASE).REG-AMBU A/S: ANNUAL REPORT 2017/18 (EARNINGS RELEASE).Q4 2017/18 ORGANIC GROWTH OF 15% (14%) WAS REALISED IN Q4 IN LOCAL CURRENCIES, BASED ON REVENUE OF DKK 729M (DKK 629M).Q4 EBIT INCREASED TO DKK 165M (DKK 134M) WITH AN EBIT MARGIN OF 22.6% (21.3%). FY 2017/18.MANAGEMENT'S OUTLOOK FOR 2018/19 IS UNCHANGED RELATIVE TO MOST RECENTLY ANNOUNCED OUTLOOK ON 4 OCTOBER 2018.FY 2017/18 REVENUE FOR FINANCIAL YEAR WAS DKK 2,606M (DKK 2,355M) BASED ON ORGANIC GROWTH IN LOCAL CURRENCIES OF 15% (14%).PROPOSES THAT DIVIDEND OF DKK 0.40 (DKK 0.37) BE PAID PER SHARE.SAYS IS ON TRACK TO REALISING TARGETS OF ITS 2020 STRATEGY..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up